Babylon Investor Conference Presentation Deck
Reconciliation of Adjusted EBITDA and Other Non-IFRS Measures
Q2-2021
($64,875)
$000s
Loss for the period
Adjustments to calculate EBITDA:
Depreciation and amortization
Finance costs and income
Tax provision / (benefit)
EBITDA
Adjustments to calculate Adjusted EBITDA:
Share-based compensation
Change in fair value of warrant liabilities
Loss on settlement of warrants
Gain on remeasurement of equity interest
Gain on sale of subsidiary
Impairment expense
Restructuring and other one-time benefit arrangements
Exchange (gain) / loss
Recapitalization transaction expense
Adj. EBITDA
Total revenue
IFRS Loss for the Period Margin %
Adjusted EBITDA Margin %
Value-based care revenue
Claims expense
Medical Loss Ratio %
Medical Margin %
Q3-2020
($37,986)
3,072
478
63
($34,373)
$2,019
(259)
($32,613)
$15,811
(240%)
(206%)
Q4-2020
($59,230)
4,956
879
1,639
($51,756)
$7,105
6,404
949
($37,298)
$40,958
(145%)
(91%)
$26,038
Q1-2021
($10,847)
5,848
978
8
($4,013)
$2,802
(3,917)
573
($4,555)
$71,293
(15%)
(6%)
$27,259
(23,917)
88%
12%
7,474
1,237
(2,501)
($58,665)
$9,542
(482)
($49,605)
$57,478
(113%)
(86%)
$39,133
(40,384)
103%
(3%)
Q3-2021
($65,975)
8,823
2,049
7
($55,096)
$7,241
396
($47,459)
$74,462
(89%)
(64%)
$55,715
(51,298)
92%
8%
Q4-2021
($232,815)
12,859
9,701
1,012
($209,243)
$26,722
(27,811)
(10,495)
941
(1,355)
148,722
($72,519)
$119,688
(195%)
(61%)
$98,745
(104,026)
105%
(5%)
Q1-2022
($91,357)
9,458
6,373
9
($75,517)
$8,402
(5,575)
447
($72,243)
$266,446
(34%)
(27%)
$246,575
(247,552)
100%
(0%)
Q2-2022
($157,079)
11,944
9,688
199
($135,248)
$10,564
(10,791)
2,375
53,224
3,848
7,350
($68,678)
$265,362
(59%)
(26%)
$244,098
(238,764)
98%
2%
Note: We are not able to reconcile projected 2022 Adjusted EBITDA or 2022 Adjusted EBITDA Margin to their respective most directly comparable IFRS measures as we are not able to forecast IFRS loss for the period on a forward-looking basis without unreasonable efforts due to the high variability and difficulty in
predicting certain items that affect IFRS loss for the period, including, but not limited to, changes in fair value of warrant liabilities, impairment expense, share-based compensation, restructuring and other one-time benefits, foreign exchange gains or losses and gains and losses on sale of subsidiaries. Adjusted
EBITDA should not be used to predict IFRS loss for the period as the difference between the two measures is variable and may be significant.
Q3-2022
($89,891)
7,477
8,617
280
($73,517)
$8,955
(1,143)
22
1,400
5,135
4,848
($54,300)
$288,898
(31%)
(19%)
$267,686
(264,283)
99%
1%
19
babylonView entire presentation